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ABSTRACT
Objective To determine the effectiveness of the provision
of whole food to enhance completion of treatment for
tuberculosis.
Design Parallel group randomised controlled trial.
Setting Three primary care clinics in Dili, Timor-Leste.
Participants 270 adults aged ≥18 with previously
untreated newly diagnosed pulmonary tuberculosis.
Main outcome measures Completion of treatment
(including cure). Secondary outcomes included
adherence to treatment, weight gain, and clearance of
sputum smears. Outcomes were assessed remotely,
blinded to allocation status.
Interventions Participants started standard tuberculosis
treatment and were randomly assigned to intervention
(nutritious, culturally appropriate daily meal (weeks 1-8)
and food package (weeks 9-32) (n=137) or control
(nutritional advice, n=133) groups. Randomisation
sequence was computer generated with allocation
concealment by sequentially numbered, opaque, sealed
envelopes.
Results Most patients with tuberculosis were poor,
malnourished men living close to the clinics; 265/270
(98%) contributed to the analysis. The intervention had
no significant beneficial or harmful impact on the
outcome of treatment (76% v 78% completion, P=0.7) or
adherence (93% for both groups, P=0.7) but did lead to
improved weight gain at the end of treatment (10.1% v
7.5% improvement, P=0.04). Itch was more common in
the intervention group (21% v 9%, P<0.01). In a subgroup
analysis of patients with positive results on sputum
smears, there were clinically important improvements in
one month sputum clearance (85% v 67%, P=0.13) and
completion of treatment (78% v 68%, P=0.3).
Conclusion Provision of food did not improve outcomes
with tuberculosis treatment in these patients in Timor-
Leste. Further studies in different settings and measuring
different outcomes are required.
Trial registration Clinical Trials NCT0019256.
INTRODUCTION
Tuberculosis remains a considerable global public
health concern with over nine million cases and 1.7
million deaths notified to the World Health Organiza-
tion in 2006.
1 Considerable progress has been made
towards achieving the millennium development goals
fortuberculosisby2015,withincidenceratesdeclining
in the past two years.
1 Central to the recommended
treatment strategy is the use of directly observed treat-
ment to ensure adherence. Intermittent or incomplete
treatment has been associated with adverse outcomes
for patients (severe disease and long term disability,
low cure rate, disease relapse, or even death) and for
public health (prolonged infectiousness and transmis-
sibility and the development of drug resistance).
A series of Cochrane reviews are examining various
methods of enhancing adherence to tuberculosis treat-
ment. One review concluded that randomised trials
provide no evidence that directly observed treatment
improves cure or rates of completion of treatment in
low and middle income countries compared with self
administered treatment.
2 Reminder systems and late
patienttracersareeffectiveinvarioussettings,although
most trials have been conducted in high income
countries.
3Theprovisionofmonetaryandotherincen-
tives to improve treatment adherence, including the
provision of cash payments and food vouchers, has
been found to be effective in some settings.
4
Food incentives are attractive because of the well
described link between malnutrition and tuberculosis;
malnourished adults are more likely to develop tuber-
culosisandtuberculosiscausesweightloss.
5Theextent
of malnutrition at diagnosis is strongly associated with
severity of lung disease, increased relapse rates, and
mortality in adults with pulmonary tuberculosis.
6-8
Specifically, Khan and colleagues have shown that
patientswithtuberculosiswhoareunderweightatdiag-
nosis and achieve a weight gain of less than 5% during
the intensive phase of treatment are at higher risk of
disease relapse during the following two years.
8
Various nutritional supplements are being used in
tuberculosis programmes in many settings and have
been advocated by the World Food Program.
9 Nutri-
tional supplements are popular with patients,
10 but a
recent Cochrane review showed unconvincing evi-
dence of a direct benefit of food supplements on a
range of clinical outcomes.
11
We investigated whether nutritional supplementa-
tion with culturally appropriate food is an effective
adjunctive therapy to enhance completion of tubercu-
losis treatment in Timor-Leste.
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Setting
Timor-Lesteisasmall,newlyindependentAsiancoun-
try with a population of around a million and a gross
domestic product of $364 (£229, €244) per person per
annum.
12Ithasahighincidenceoftuberculosisbutlow
ratesofHIVanddrugresistance.
13Thereisawellfunc-
tioning National TB Control Program (NTP), which
uses the WHO strategy known as DOTS (directly
observed treatment).
14 The study was conducted in
three community clinics in the capital city, Dili. The
clinicsweregovernment,private,andchurchoperated
(one of each) and covered geographically distinct
zones within the city. Enrolment started on 16 March
and was completed on 9 November 2005, with follow-
up of all patients completed by July 2006. A political
crisis starting on 28 April 2006 led to civil conflict in
Dili for several months, including disruption to deliv-
ery of health services and the displacement of an esti-
mated 70% of Dili’s population to camps within the
city or to the rural districts.
15
Participants and procedures
The study sample consisted of patients with newly
diagnosed pulmonary tuberculosis (positive and nega-
tive results on sputum smear tests). A nurse or physi-
cian examined all outpatients and referred those with
possible tuberculosis to the tuberculosis nurse for
further examination, including sputum collection
(spot/morning/spot). Trained laboratory technicians
examinedsputumbyusingthestandardZiehl-Neelsen
methodondirectsmears.Thediagnosisoftuberculosis
in patients with negative smear results conformed to
the NTP guidelines (no clinical response to 14 days’
treatment with broad spectrum antibiotics and chest x
ray picture suggestive of active tuberculosis). The
WHO reference laboratory in Adelaide, Australia,
provided quality control of the tuberculosis labora-
tories.Allparticipantsreceivedroutinecare,including
drugs, default tracing, and clinical monitoring accord-
ing to the NTP guidelines. Patients with tuberculosis
were eligible for inclusion if they were aged ≥18 and
agreedtoreceivetuberculosistreatmentatthediagnos-
ing clinic for eight months. Exclusion criteria were
pregnancy and previous treatment for tuberculosis
for more than one month.
Patients were asked to attend the clinic according to
routinepractice(fiveorsixmorningsaweek)toreceive
directlyobservedtreatment(intensivephasewithdaily
rifampicin, isoniazid, pyrazinamide, and ethambutol
daily for two months, followed by a continuation
phase with isoniazid and ethambutol daily for six
months) in appropriate doses (see table A on
bmj.com). Treatment was administered fortnightly in
the continuation phase.
Randomisation and blinding
At each study site a research assistant randomly allo-
catedstudyparticipantstotheinterventiongroup(sup-
plementaryfood)orcontrolgroup(nutritionaladvice).
Anindependentstatisticiancomputer generateda ran-
domallocationsequencewithrandomlyvaryingblock
sizes in Stata (version 8). The sequence was concealed
fromallinvestigatorswithsequentiallynumberedopa-
que sealed envelopes prepared distant from the study
site. Allocation was stratified by community health
clinic and by diagnosis of tuberculosis (smear positive
and smear negative). Both participants and treatment
providers were aware of an individual’s allocation sta-
tus after randomisation. An independent observer
(PM, based in Darwin), who was blinded to the inter-
ventionreceivedbythepatients,however,determined
the primary outcome (treatment completion).
Study intervention
At enrolment, the research assistant gave patients ran-
domised to nutritional advice (control group) verbal
and written advice concerning the types of locally
available food that would constitute a balanced diet
Table 1 |Estimated nutritional value of average serving size
for daily meal consumed by patients in intervention group in
intensive phase of treatment
Nutrient Quantity
%RDI16
Male Female
Energy (kJ) 1800 24 25
Protein (g) 18.4 34 48
Carbohydrate (g) 55.6 17 17
Vitamin C (mg) 24.2 63 64
Vitamin A (μg) 363 47 62
Iron (mg) 3.1 45 21
Zinc (mg) 3 25 45
Folate (μg) 60 18 18
RDI=recommended daily intake.
Loss to follow-up (n=1, 1%)
Excluded (n=563)
  Ineligible (n=245, 44%)
  Other exclusions (n=266, 47%)
  Refused to participate (n=52, 9%)
Loss to follow-up (n=4, 3%)
Intervention group
Allocated to food intervention (n=137, 50.7%) 
Received allocated intervention (n=137, 100%)
Control group
Allocated to nutritional advice only (n=133, 49.3%)
Received allocated intervention (n=133, 100%)
Patients assessed for eligibility (n=833)
Randomised (n=270)
Contribute to analysis (n=136, 99%) Contribute to analysis (n=129, 97%)
Fig 1 | Flow of participants through study. Original sample included all diagnoses of
tuberculosis in three clinics during study period, March 2005 to July 2006. Ineligible patients
included 62 (25%) previously treated for tuberculosis, 176 (72%) aged <18, and 7 (3%)
pregnant women. Others excluded, according to selection criteria, included 211 (79%)
transferred out before enrolment, 42 (16%) community directly observed treatment (clinician’s
decision), 7 (3%) unable to agree to complete treatment, 5 (2%) default before enrolment, 1
(0.5%) died before enrolment. Refusals: 43 (83%) unwilling to attend for midday meal; 9 (17%)
chose community DOT (unable to attend clinic, self assessed disease severity). Loss to follow-
up means transferred out to another clinic during treatment
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.comlikely to assist cure of tuberculosis. These patients
received routine care and were asked to attend the
clinic at the usual time (early morning).
Patients in the intervention group were asked to
attend the clinic at mid-day. In addition to usual treat-
ment for tuberculosis, they received food every time
they attended the clinic. In the intensive phase, each
day they were provided with one bowl of feijuada, a
locally popular meat, red kidney beans, and vegetable
stew with rice, at the clinic (table 1 and table B on
bmj.com). This meal was rich in energy, protein, and
micronutrients.
16 The ingredients were obtained from
localsupplierswithfreshproduceboughtonthedayof
consumptionandotherproduceboughtinbulk.Inthe
intensive phase of treatment a research assistant
directlyobservedfoodintake.Duringthecontinuation
phase of treatment, patients were given a food parcel
containing unprepared food to take home (red kidney
beans, rice, and oil). The quantities were calculated to
provideonemealadayforoneadult.Atrandominter-
vals during the study period two authors (NM and
PMK) checked the quality and quantity of produce.
An independent assessment was carried out to ensure
thesafepreparationandadministrationoftheintensive
phase intervention.
Outcome measures
We used standard Timorese NTP definitions of treat-
ment outcome (see table C on bmj.com). The primary
outcome measure was completion of treatment (clear-
anceofacidfastbacillifromthesputumaftertreatment
or the completion of eight months of treatment, or
both). Secondary outcome measures were adherence
to treatment, clinical improvement, and adverse
events. Adherence was measured by recording clinic
attendance and directly observed treatment (daily in
the intensive phase and fortnightly in the continuation
phase) and through interview and pill counts (in the
continuationphase).Allothermeasurementswereper-
formed weekly during the intensive phase and fort-
nightly during the continuation phase of treatment.
Clinicalimprovementwasmeasuredbyrecordedclin-
ical symptoms and weight gain. Percentage of weight
changewascalculatedasthedifferenceinweightattwo
times(forexample,diagnosisandeightweeks)divided
by the weight at the earlier time, multiplied by 100.
Adverse events were actively recorded with a standar-
dised questionnaire.
Sample size
Based on existing default rates of 13%, we calculated
that we needed to enrol 270 patients to detect a reduc-
tion in the primary outcome (default rate) to an accep-
table 3%, with 80% power and an α of 0.05.
Statistical analysis
Analysis was by intention to treat. We used indepen-
dent t tests and Kruskal-Wallis tests to compare the
difference in continuous variables between groups
and Pearson’s χ
2 test to compare the association
between treatment group and categorical variables.
Relative risks with 95% confidence intervals were cal-
culatedwithstandardmethods.Ratesofcompletionof
treatment and clinical outcomes were also analysed
with logistic regression with adjustment for prespeci-
fied confounding factors. Kaplan-Meier survival esti-
mates were used to examine the relation between the
intervention and time to default. Significance was
based on a two tailed P<0.05. Analysis of secondary
outcomes was regarded as “hypothesis generating.”
No adjustment was made for multiple comparisons.
All statistical analyses were performed with Stata (ver-
sion 9.1).
RESULTS
During the study enrolment period tuberculosis was
diagnosed in 833 patients at the three clinics in Dili.
Of these, 270 patients were recruited into the study
Table 2 |Baseline characteristics of study participants. Figures are numbers (percentages)
unless stated otherwise*
Control
(n=133)
Intervention
(n=137)
Total
(n=270)
Demographic characteristics
Mean (SD) age (years) 32.6 (13.4) 33.9 (14.2) 33.3 (13.8)
Male 86 (65) 89 (65) 175 (65)
Unemployed 60 (45) 56 (41) 116 (43)
Income ($/month):
0 103 (80) 106 (80) 209 (80)
1-100 10 (8) 19 (14) 29 (11)
>100 15 (12) 8 (6) 23 (9)
Mean (SD) distance to clinic (km) 2.4 (1.8) 2.4 (1.4) 2.4 (1.6)
Clinical characteristics
Median (IQR) duration of illness (weeks)† 8 (4-28) 8 (4-20) 8 (4-24)
BMI:
<16.0 40 (30) 44 (32) 84 (31)
16.0-16.9 30 (23) 33 (24) 63 (24)
17.0-18.4 35 (27) 31 (23) 66 (25)
>18.5 27 (20) 28 (21) 55 (20)
Mean (SD) weight (kg) 43.6 (7.6) 43.0 (7.3) 43.3 (7.5)
Smear positive 38 (29) 41 (30) 79 (29)
IQR=interquartile range; BMI=body mass index.
*Data missing for age (1 intervention), income (5 control, 4 intervention), distance to clinic (7 control, 6
intervention), duration of illness (2 controls), BMI (1 control, 1 intervention).
†Kruskal-Wallis test.
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Fig 2 | Kaplan-Meier plot showing time to default by group.
Hazard ratio for time to default 1.10 (0.66 to 1.82), P=0.7. Not
significantly influenced by age, sex, or result of smear test
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vention, and only five (1.9%) were transferred to other
clinics and did not contribute a primary outcome.
After randomisation, the two groups of patients had
similar demographic characteristics (table 2). Most
enrolled patients were young (mean age 33.3), male
(175/270, 65%), poor (209/261 (80%) had no formal
income), and lived close to the clinic (mean distance
2.4km).Enrolledpatientshadhadsymptomsoftuber-
culosisforameanofeightweeksbeforetheirdiagnosis.
There were no significant differences in the nature,
duration, or frequency of tuberculosis symptoms or
healthcareseekingbehaviourbetweenthe twogroups.
Mostpatients(213/268,80%)weremalnourished,with
almost one in three in WHO’s severely malnourished
range (body mass index (BMI) <16.0).
17 A relatively
small proportion (79/270, 29%) of patients had posi-
tive results on sputum smear tests; this was similar in
both groups and consistent with previous studies in
Timor-Leste.
14
For the primary outcome of completion of treat-
ment, there was no significant difference between the
intervention (100/129, 76%) and control (103/136,
78%) groups (relative risk 0.98, 95% confidence inter-
val 0.86 to 1.11) (table 3). This is equivalent to a risk
difference of −2% (−11% to 9%). In patients with posi-
tive smear results, there was a non-significant differ-
ence in completion of treatment (31/40, 78% for the
intervention group v 25/37, 68% for controls, 1.15,
0.87 to 1.52; see table 4). The civil conflict dramati-
cally increased the default rate of those patients (68,
25%) still receiving treatment after 28 April 2006 and
led to a significant decrease in treatment completion
(168/199(84%)beforeconflictv35/66(53%)aftercon-
flict; 1.58, 1.26 to 2.01; P<0.001).
Secondary outcomes included adherence to treat-
ment, weight gain, symptomatic improvement in all
patients, and sputum smear clearance in the subgroup
with positive smear test results. Almost all non-com-
pletion was because of default from treatment: there
was only one death and one treatment failure during
the study (see table C on bmj.com for definitions).
While the default rate was higher than expected, most
of this occurred in the final weeks of treatment. Early
default was rare (fig 2). Over half of the defaults were
associated with the civil conflict (31/60). The inter-
vention had no significant effect on default rates or
timetodefault.Whileparticipantswerereceivingtreat-
ment,adherencewashigh,particularlyinthecontinua-
tion phase (98%). In the intensive phase, adherence
was significantly lower in the intervention group
(86.7%) than in the control groups (91.4%, P=0.02).
Theprovisionoftuberculosistreatmentrapidlyalle-
viated or considerably reduced most of the baseline
symptoms. Haemoptysis and fever virtually disap-
peared during the first two months of treatment.
Cough remained in most patients after four weeks
and in a significant minority after eight weeks of treat-
ment (table 3 and fig 3). The food intervention didnot
significantly hasten improvement in symptoms.
Weight gain was significantly greater in the inter-
vention group, both at the end of the intensive phase
(5.2% increase for intervention v 3.5% for controls,
P=0.04) and at the end of treatment (10.1% v 7.5%,
P=0.04)(table 3andfig4).Thisrelationwaslessstrong
in the subgroup with positive sputum smear results. In
a post hoc analysis of those who were underweight at
baseline (BMI <18.5, n=209 with 18 missing values),
the food intervention led to a significant likelihood of
adequate weight gain (that is, more than 5%) at two
months compared with the control group (66/110
(60%)fortheinterventiongroupv31/82(38%)forcon-
trols; crude odds ratio 2.47, 1.37 to 4.44; P=0.003).
Afteradjustmentfor age,sex, height,and smearresult,
the adjusted odds ratio was 2.69 (1.44 to 5.00;
P=0.002). The result was even more striking in the
Table 3 |Primary and secondary outcomes and adverse events by intention to treat analysis
in all patients*. Figures are numbers (percentages) unless stated otherwise
Outcome
Control
(n=129)
Intervention
(n=136)
RR/mean difference†
(95% CI, P value)
Primary outcome
Treatment success
Overall 100 (78) 103 (76) 0.98 (0.86 to 1.11, 0.7)
Before conflict 82 (85) 86 (84) 1.0 (0.88 to 1.12, 1.0)
After conflict 18 (56) 17 (50) 0.89 (0.56 to 1.40, 0.6)
Secondary outcomes
Mean % (SD) compliance:
Intensive 91.4 (13.3) 86.7 (18.6) −4.7 (−0.8 to −8.6, 0.02)
Continuation 98.3 (6.7) 98.2 (6.7) 0 (−1.7 to 1.7, 1.0)
Mean % (SD) weight gain:
8 weeks 3.5 (6.3) 5.2 (6.2) 1.7 (0.1 to 3.2, 0.04)
32 weeks 7.5 (7.6) 10.1 (9.6) 2.6 (0.1 to 5.1, 0.04)
Cough clearance:
4 weeks 54 (42) 52 (43) 1.02 (0.76 to 1.36, 0.9)
8 weeks 60 (61) 57 (58) 0.94 (0.75 to 1.18, 0.6)
32 weeks 76 (80) 80 (84) 1.05 (0.92 to 1.20, 0.4)
Adverse events:
Itch 12 (9) 28 (21) 2.27 (1.20 to 4.26, 0.008)
*Data missing for success (4 control and 1 intervention); compliance (1 control in intensive phase, 13 control
and 14 intervention in continuation phase); weight (11 control and 16 intervention at 8 weeks, 42 control and
40 intervention at 32 weeks); cough (3 control and 14 intervention at 4 weeks, 35 control and 38 intervention
at 8 weeks, 38 control and 42 intervention at 32 weeks).
†Relative risk for comparisons of categorical variables or mean difference for comparisons of means of
continuous variables.
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Fig 3 | Cough clearance in patients with tuberculosis
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.comsubgroup who were severely underweight (BMI
<16.0: 22/39 (56%) in intervention group v 10/38
(26%) controls), in whom the crude odds ratio was
3.62 (1.39 to 9.47; P=0.009) and the adjusted odds
ratio was 3.37 (1.25 to 9.10; P=0.02).
In patients with positive sputum smear results, there
was a non-significant improvement in sputum clear-
ance at one month (18% absolute improvement,
P=0.13). Forthis analysis, therewas a substantialnum-
berofmissingvaluesbecauseofdefault,refusal,inabil-
ity to cough, or laboratory error. Patients with missing
data, however, were similar at baseline when com-
pared with those who were included in the analysis.
Over half the participants reported at least one
adverse event potentially attributable to tuberculosis
treatment. These were minor adverse events that
occurred mostly during the first week of treatment
and resolved with symptomatic treatment. None of
the patients had to stop treatment. The main com-
plaints were influenza syndrome, itch, and nausea.
Itch with or without rash was more than twice as likely
tooccurintheinterventiongroup(table 3).Inpatients
withpositivesputumsmearresults,theassociationwas
even more striking (relative risk 11.1, 1.51 to 81.5).
Multivariate analyses with adjustment for sputum
smear result, clinic type, sex, education, occupation,
income, and distance from the clinic did not change
the results for outcome measures or adverse events.
DISCUSSION
In this randomised controlled trial to examine the use
offoodasanincentivetoimproveoutcomewithtuber-
culosis treatment we found that food incentives led to
modestly higher weight gain but did not result in a sig-
nificant improvement in adherence to treatment or
successful completion of treatment. Substantial
improvement in completion of treatment (≥10%) is
unlikely in this setting. Smaller beneficial (or harmful)
effects cannot be excluded.
Our participants adhered well to treatment, and
food, though expensive, was readily available at the
urban study site during most of the study period. In
other settings—for example, in sub-Saharan Africa
where treatment completion rates are generally
lower
1 and food insecurity is widespread
18—the result
might be different.
Conflicting evidence of effectiveness in previous trials
The influence of macronutrient or micronutrient sup-
plementation on outcomes of tuberculosis treatment
has been inconclusive in the limited number of trials
reported to date and has been summarised in a recent
Cochrane review
11 and in table 5. Reported outcome
measures have included sputum smear clearance,
symptomatic improvement, weight gain during treat-
ment, cure, recurrence of tuberculosis, and death. Our
studyprovidesthemostcomprehensivereportonrele-
vant outcomes to date and reports on adverse events.
Given the potential for benefit of nutritional inter-
vention, further studies on the role of whole food are
warranted.
In this study, the only outcome significantly asso-
ciated with the intervention was weight gain. Similar
findings have been noted in studies in Singapore
19
and in Tanzania
20 but not in others
21-25. Specifically,
patientswhowereunderweightatbaselineweresignif-
icantly more likely to gain more than 5% during the
intensive phase of treatment, an important indicator
of improved long term treatment outcome.
8 This sug-
gests that, although a food intervention seems to have
little or no effect on treatment adherence and comple-
tionrates,thisinterventionmightstillbeworthconsid-
ering in patients with tuberculosis who are
malnourished at diagnosis. This represents an
Table 4 |Primary and secondary outcomes and adverse events by intention to treat analysis
in patients with positive sputum smear results*. Figures are numbers (percentages) unless
stated otherwise
Outcome
Control
(n=37)
Intervention
(n=40)
RR/mean difference†
(95% CI, P value)
Primary outcome
Treatment success:
Overall 25 (68) 31 (78) 1.15 (0.87 to 1.52, 0.3)
Before conflict 24 (77) 29 (91) 1.17 (0.94 to 1.46, 0.2)
After conflict 1 (17) 2 (25) 1.5 (0.17 to 12.9, 0.7)
Secondary outcomes
Clearance at 4 weeks 18 (67) 22 (85) 1.27 (0.92 to 1.74, 0.13)
Mean % (SD) compliance:
Intensive 93.5 (8.2) 89.9 (18.7) −3.6 (−10.2 to 3.1, 0.3 )
Continuation 97.1 (9.7) 96.8 (10.3) −0.4 (−5.0 to 4.3, 0.9)
Mean % (SD) weight gain:
8 weeks 5.9 (8.0) 6.6 (7.8) 0.6 (−3.0 to 4.3, 0.7)
32 weeks 11.7 (9.0) 13.8 (13.1) 2.1 (−3.9 to 8.2, 0.5)
Cough clearance:
4 weeks 17 (46) 16 (43) 0.94 (0.57 to 1.56, 0.8)
8 weeks 19 (63) 21 (62) 0.97 (0.67 to 1.43, 0.9)
32 weeks 19 (83) 25 (86) 1.04 (0.82 to 1.32, 0.7)
Adverse events:
Itch 1 (3) 12 (30) 11.1 (1.51 to 81.5, 0.01)
*Data missing for success (1 control and 1 intervention); sputum clearance (11 control and 15 intervention;
compliance (1 control in intensive phase, 3 control and 4 intervention in continuation phase); weight (1 control
and 3 intervention at 8 weeks, 12 control and 14 intervention at 32 weeks); cough (1 control and 4 intervention
at 4 weeks, 8 control and 7 intervention at 8 weeks, 15 control and 12 intervention at 32 weeks).
†Relative risk for comparisons of categorical variables or mean difference for comparisons of means of
continuous variables.
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Fig 4 | Weight gain in patients with tuberculosis
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 5 of 8important incremental step in knowledge and contri-
butes to policy relevant evidence.
Symptoms improve with tuberculosis treatment,
andallbutonestudy
24havefailedtoshowasignificant
additional improvement with adjunctive nutrition.
2126
Earlysputumclearancecontributestoadecreasedper-
iodofinfectiousnessandcanhaveamajorinfluenceon
tuberculosis control. Our study showed encouraging
trends in sputum smear clearance and cure rates in
patients with positive sputum smears but was under-
powered to examine these outcomes in the subgroup
analysis. The findings from other studies are conflict-
ing for this outcome, with one Mexican and two Indo-
nesian studies showing more rapid
22 or more
complete
2728sputumsmearconversionintheintensive
phase, a finding that has so far not been replicated
elsewhere.
20252930 Mortality during tuberculosis treat-
ment is rare in Timor-Leste, and so it is unsurprising
that we were unable toshowany influenceofthe inter-
vention on this outcome. Even in areas with high HIV
prevalence, where death is more common, no effect
has been found.
25262931
Study limitations
For ethical reasons, we were required to differentiate
between patients in the control and intervention
groupsbyspacingtheirattendanceattheclinic:control
groupinthe morningand interventiongroupatlunch-
time. Qualitative data derived from participants in the
intervention group suggest that, despite the over-
whelming acceptability of the meal, some people
expressed shyness about eating at the clinic, while
others complained about time inflexibility relating to
clinic attendance. This might have been an unantici-
pated barrier to effective treatment, counteracting
anypositiveeffectoffoodprovisionandmightexplain
the lower than expected adherence to treatment in the
intensive phase. A cluster randomised trial, with a
much larger sample size, might have been a more
appropriate study design.
The conflict in Dili in the later part of the study
clearly affected adherenceto treatment in a substantial
minority of patients. This led to a lower than expected
overall rate of treatment completion. There was, how-
ever, no significant difference in the intervention or
control groups during this period, so this is unlikely
to have explained the negative result.
The randomised controlled trial design minimises
confounding and maximises study validity. Our
study shows that high quality intervention studies can
beconductedsuccessfullyeveninthemostchallenging
setting. The strict selection of participants, however,
might have excluded patients most likely to benefit.
Our findings might have been different if we included,
for example, those patients who were admitted to
albuergues (hostels) for the intensive phase. In Dili,
albuergues were designed to accommodate patients
with certain characteristics, including high risk of
non-adherence. It is also arguable that the true impact
of food on treatment outcome and adherence should
be measured differently. We lacked the necessary
funding and equipment on site to measure potential
immunologicalorbiologicalparameters.Additionally,
rather than concentrate on individual treatment
Table 5 |Summary of randomised controlled trials of nutritional interventions and tuberculosis (TB) by year of publication (adapted from Abba
11)i n
community based adult patients unless stated otherwise
Study
No of
patients Diagnosis Othercriteria
HIV co-
infection Intervention
Risk of
bias*
Outcome measures, significant nutrition effect
Adverse
events Mortality Cure
Sputum
conversion
Symptomatic
improvement
Weight
change QoL
Hanekom, 1997,
21
South Africa
85 PTB Hospitalised
children
Excluded Vitamin A High NM NM NM No no NM NM
Morcos, 1998,
23 Egypt 24 PTBandEPTB Children NA Vitamin D High NM NM NM NM No NM NM
Karyadi, 2002,
22
Indonesia
110 Sm+ PTB — NA Vitamin A and Zn High NM No Yes NM No Yes NM
Schon,2003,
24Ethiopia 120 Sm+ PTB — Included Arginine High NM NM Yes† Yes† Yes† NM NM
Paton, 2004,
19
Singapore
36 PTB Hospitalised,
wasted
Excluded High energy
and protein
Medium NM NM NM NM Yes No NM
Range, 2005,
20 29
Tanzania
530 Cu+ or sm+
PTB
— Included Multivitamins, Zn Low No NM No NM Yes NM NM
Perez-Guzman, 2005,
28
Mexico
21 Cu+ PTB Hospitalised Excluded High cholesterol High NM NM Yes No NM NM NM
Nursyam, 2006,
27
Indonesia
67 Cu+ PTB Advanced
disease
Excluded Vitamin D High NM NM Yes NM NM NM NM
Seyedrezazadeh,
2006,
30 Iran
42 Cu+ PTB — NA Vitamin A and Se High NM NM No NM No NM NM
Semba, 2007,
31 Malawi 1148 Sm+ PTB — Included Multivitamins Low No NM NM NM NM NM NM
Villamor, 2008,
25
Tanzania
887 Sm+ PTB — Included Multivitamins Medium No Yes No NM NM NM NM
Wejse, 2009,
26
Guinea-Bissau
365 PTBandEPTB — Included Vitamin D Low No NM No No No NM No
Current study 270 PTB — NA Whole food Low No No No No Yes NM Yes
NA = not available; NM = outcome not measured; Qol=quality of life; PTB = pulmonary tuberculosis (sputum smear positive and negative); Sm+ PTB = smear positive; cu+ PTB = culture
positive; PTB and EPTB = pulmonary and extrapulmonary TB.
*According to Cochrane review (excluding current study): low risk = adequate randomisation, blinding and follow-up; medium = one of these inadequate; high = all are inadequate.
†No effect in patients with HIV co-infection.
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could be measured in the context of management of a
tuberculosis programme. Perhaps the wider influence
on the reputation of the clinics might lead to a greater
willingnesstocomeforbothdiagnosisand remaintak-
ing treatment.
An expensive intervention
Food provision is an expensive and logistically com-
plex intervention. In this study, the introduction of
food incentives involved building works, storage
costs, purchase of equipment and consumables, trans-
port, and salary costs, in addition to the actual food
provided. When the true costs of these items are
taken into account, we estimated the intensive phase
costs at$2-3 (£1.2-1.8,€1.3-1.95)a meal,witha similar
weekly cost for the food parcels in the continuation
phase. This effectively doubles the cost per patient of
tuberculosis treatment. There would need to be sub-
stantially stronger evidence of effectiveness of food to
make this a cost effective intervention.
Conclusion
This randomised control trial of food incentive to
improve treatment outcome was successfully con-
ductedinTimor-Leste.Inthissettingfoodsupplemen-
tation did not significantly improve treatment
adherence or treatment outcome. Further studies
with a larger sample size and a wider selection of
patientsindifferentsettingswillberequiredtoconfirm
orrefutethisfinding.Assessmentofthe impactoffood
supplementationasastrategytoimprovemanagement
of tuberculosis programmes more widely and on the
biological and immunological determinants of treat-
ment response is also appropriate.
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